<DOC>
	<DOCNO>NCT00378014</DOCNO>
	<brief_summary>The study design show everolimus initiation together reduction thereafter discontinuation calcineurin inhibitor ( CNI ) improve significantly renal function de novo liver transplant recipient compare continuation CNI-based treatment .</brief_summary>
	<brief_title>Preservation Renal Function Liver Transplant Recipients With Certican Therapy</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Males females 18 70 year old Liver transplant recipient ( live decease donor ) Patients allograft biopsy contraindicate Recipients multiple solid organ transplant patient already receive transplant past HCV positive patient need active antiviral treatment ( HCV positive patient without active antiviral treatment allow ) HIV positive patient Patients breast feed Patients current severe systemic infection Presence hypersensitivity drug similar CerticanÂ® ( e.g . macrolides ) Preexisting ( i.e . related CNIdamage ) renal dysfunction , accord judgment investigator , significantly improve transplantation ( i.e. , example , patient expect cGFR 50ml/min 4 week post transplantation ) Patients receive Simulect prior study . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Liver transplantation , everolimus , CNI</keyword>
</DOC>